Meeting
2011 ASCO Annual Meeting
The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.
Authors
A. J. Montero
University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
A. J. Montero , S. Gluck , G. d. L. Lopes Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research
Track
Health Services Research
Sub Track
Health Services Research
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6060)
Abstract #
6060
Poster Bd #
42H
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer.
First Author: James Dickerson
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study.
First Author: Xin Qu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz